ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed herewith the Newspaper Publication dated 11th May, 2024.11-05-2024
11-05-2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find attached herewith the intimation dated 10th May, 2024 received from our RTA.10-05-2024
Alembic Pharma Q4 Results Review - New Launches In U.S., Capacity Utilisation To Drive Growth: Nirmal Bang
Domestic business grew by ~3% YoY to Rs 5.03 billion.10-05-2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Please find attached the Audio Recording of the Post Results Conference call.09-05-2024
Q4FY24 Quarterly & FY24 Annual Result Announced for Alembic Pharmaceuticals Ltd.
Pharmaceuticals company Alembic Pharmaceuticals announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Net Sales increased 8% to Rs 1,517 crore. Net Profit up 17% to Rs 178 crore EBITDA up 29% to Rs 263 crore FY24 Financial Highlights: Net Sales grew 10% to Rs 6,229 crore. Net Profit up 80% to Rs 616 crore EBITDA up 41% to Rs 961 crore. Shaunak Amin, MD, Alembic Pharmaceuticals said “India Branded Business continues to work on improving the execution ability both in quality & scale. The Specialty and Animal health segment witnessed robust growth. The outlook for the US business appears better, with the commercialization of new facilities and launches set to scale up along with continued progress in achieving cost improvements. The Ex-US generics and the API business maintained a steady continuous growth.” Result PDF09-05-2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find enclosed herewith the Investor Presentation of the Audited Financial Results of the Company for the quarter and financial year ended March 31, 2024. We request you to kindly take the same in record.09-05-2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith the Press Release on the Audited Financial Results for the quarter ended March 31, 2024.09-05-2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Audited Financial Results For The Quarter And Financial Year Ended March 31, 2024
The exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its Meeting held today inter alia approved the Audited Financial results for the Quarter and Financial year ended March 31, 2024 and recommended dividend of Rs. 11/- (550%) per Equity Share.09-05-2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Board Meeting Outcome for Outcome For Board Meeting
The exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today Approved the Audited Financial Results for the quarter and financial year ended'''' 31st March, 2024, and Recommended a dividend of Rs. 11/- (550%) per Equity Share.09-05-2024